News of Note—Sanofi, ImmusanT and more

newspaper
(Pixabay)

Here is some other vaccine news of note for the week:

> Dyadic will collaborate with Sanofi to explore how its C1 gene expression platform can be applied to Sanofi's vaccine and biologic offerings. The platform aims to speed development and reduce production costs for biologics. Release

> ImmusanT picked up funding from JDRF to work on a Type 1 diabetes vaccine. FierceBiotech article

> A drug combo containing a cancer vaccine showed promise against melanoma in a preclinical study. Release

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.